{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:25:51Z","timestamp":1761182751250,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2007]]},"DOI":"10.1007\/s10156-007-0539-2","type":"journal-article","created":{"date-parts":[[2007,11,2]],"date-time":"2007-11-02T10:29:55Z","timestamp":1193999395000},"page":"296-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antibacterial activity and PK\/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and \u03b2-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia"],"prefix":"10.1016","volume":"13","author":[{"given":"Akira","family":"Ohno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Intetsu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s10156-007-0539-2_bib0005","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1179\/joc.2005.17.6.628","article-title":"Evaluation of antimicrobial treatments in children with acute otitis media in Spain: a pharmacokinetic-pharmacodynamic (PK\/PD) approach","volume":"17","author":"Beobide","year":"2005","journal-title":"J Chemother"},{"key":"10.1007\/s10156-007-0539-2_bib0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.11150\/kansenshogakuzasshi1970.78.604","article-title":"Successful treatment of \u03b2-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis with high-dose ceftriaxone administration","volume":"78","author":"Sudo","year":"2004","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1007\/s10156-007-0539-2_bib0015","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2165\/00003495-200565080-00005","article-title":"Bacterial meningitis in children: critical review of current concepts","volume":"65","author":"Yogev","year":"2005","journal-title":"Drugs"},{"key":"10.1007\/s10156-007-0539-2_bib0020","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1128\/AAC.48.5.1509-1514.2004","article-title":"Rapidly increasing prevalence of \u03b2-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis","volume":"48","author":"Hasegawa","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-007-0539-2_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.diagmicrobio.2005.02.009","article-title":"Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002","volume":"52","author":"Yamaguchi","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1007\/s10156-007-0539-2_bib0030","first-page":"39S","article-title":"Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern","volume":"117","author":"File","year":"2004","journal-title":"Am J Med"},{"key":"10.1007\/s10156-007-0539-2_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2125.1999.00850.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"47","author":"Begg","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1007\/s10156-007-0539-2_bib0040","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2165\/00003495-198835060-00002","article-title":"Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration","volume":"35","author":"Brogden","year":"1988","journal-title":"Drugs"},{"key":"10.1007\/s10156-007-0539-2_bib0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003088-198917040-00002","article-title":"Clinical pharmacokinetics of ceftriaxone","volume":"17","author":"Yuk","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1007\/s10156-007-0539-2_bib0050","first-page":"26","article-title":"Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model","volume":"77","author":"Stoeckel","year":"1984","journal-title":"Am J Med"},{"key":"10.1007\/s10156-007-0539-2_bib0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0924-8579(02)00010-9","article-title":"Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA","volume":"19","author":"Karlowsky","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1007\/s10156-007-0539-2_bib0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003495-198427060-00001","article-title":"Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"27","author":"Richards","year":"1984","journal-title":"Drugs"},{"issue":"Suppl A","key":"10.1007\/s10156-007-0539-2_bib0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jac\/38.suppl_A.141","article-title":"Relevance of the Alexander Project: pharmacodynamic considerations","volume":"38","author":"Drusano","year":"1996","journal-title":"J Antimicrob Chemother"},{"year":"2003","series-title":"Manual of clinical microbiology","author":"Murray","key":"10.1007\/s10156-007-0539-2_bib0070"},{"year":"2006","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\u2013seventh edition: approved standard M7-A7.","key":"10.1007\/s10156-007-0539-2_bib0075"},{"year":"2006","series-title":"Performance standards for antimicrobial susceptibility tests; 16th informational supplement M100-S16.","key":"10.1007\/s10156-007-0539-2_bib0080"},{"issue":"Suppl 1","key":"10.1007\/s10156-007-0539-2_bib0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/48.suppl_1.17","article-title":"Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests","volume":"48","author":"MacGowan","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-007-0539-2_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s10156-007-0539-2_bib0095","first-page":"283","article-title":"Antibacterial activity of ceftriaxone against various clinical strains isolated in 2004","volume":"58","author":"Matsuzaki","year":"2005","journal-title":"Jpn J Antibiot"},{"key":"10.1007\/s10156-007-0539-2_bib0100","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3109\/00498258709167406","article-title":"Plasma protein binding of ceftriaxone","volume":"17","author":"Popick","year":"1987","journal-title":"Xenobiotica"},{"key":"10.1007\/s10156-007-0539-2_bib0105","first-page":"697","article-title":"Application of the MIC breakpoints based on pharmacokinetics and pharmacodynamic parameters in the clinical laboratory","volume":"56","author":"Komatsu","year":"2003","journal-title":"Jpn J Antibiot"},{"issue":"Suppl 1","key":"10.1007\/s10156-007-0539-2_bib0110","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X07708280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X07708280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-007-0539-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:45:30Z","timestamp":1761158730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X07708280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"alternative-id":["S1341321X07708280"],"URL":"https:\/\/doi.org\/10.1007\/s10156-007-0539-2","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2007]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibacterial activity and PK\/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and \u03b2-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-007-0539-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}